Key points are not available for this paper at this time.
VEGFR 표적 치료 후 진행한 신세포암 환자에서 카보잔티닙은 에버로리무스보다 무진행 생존 기간이 더 길었다. (Exelixis의 자금 지원; METEOR ClinicalTrials.gov 번호 NCT01865747.)
Building similarity graph...
Analyzing shared references across papers
Loading...
Toni K. Choueiri
Bernard Escudier
Thomas Powles
New England Journal of Medicine
University College London
Washington University in St. Louis
Dana-Farber Cancer Institute
Building similarity graph...
Analyzing shared references across papers
Loading...
Choueiri 등(Fri,)이 이 질문을 연구했다.
www.synapsesocial.com/papers/69d7c01a3b601d7be3ae2aef — DOI: https://doi.org/10.1056/nejmoa1510016